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Objective: to understand the meaning of medication therapy for schizophrenic patients and 
formulate a theoretical model about the study phenomenon. Method: a qualitative approach 
was employed, using Symbolic Interactionism as the theoretical and Grounded Theory as the 
methodological framework. The research was developed between 2008 and 2010 at three 
community mental health services in the interior of the State of São Paulo – Brazil. Thirty-six 
patients and thirty-six family members were selected through theoretical sampling. The data 
were mainly collected through open interviews and observation and simultaneously analyzed 
through open, axial and selective coding. Results: the meaning of the pharmacotherapy is 
centered on the phenomenon “Living with a help that bothers”, which expresses the patients’ 
ambivalence towards the medication and determines their decision making. The insight, access, 
limitations for self-administration of the drugs and interactions with family members and the 
health team influenced the patient’s medication-related behavior. Conclusion: the theory 
presented in this study provides a comprehensive, contextualized, motivational and dynamic 
understanding of the relation the patient experiences and indicates potentials and barriers to 
follow the medication treatment.
Descriptors: Schizophrenia; Self Medication; Interpesonal Relations; Patient Satisfaction; 
Psychotropic Drugs; Medication Adherence.
The meaning of pharmacological treatment
for schizophrenic patients1
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Introduction
Schizophrenia is a potentially disabling chronic 
condition that causes a great impact on the patients, 
families and society. Besides the subjective experience 
of psychotic symptoms, the disorder affects the 
individual’s quality of life and is associated with 
significant functional losses(1).
Continuous medication treatment is fundamental to 
control the symptoms of the disorder(2) when associated 
with other therapeutic modalities, such as psychotherapy, 
psychoeducation, sociotherapy, occupational therapy, 
among others.
The lack of adherence to the pharmacological 
treatment is associated with the exacerbation of 
symptoms, worse prognosis, repeated internment, 
high costs and unnecessary adjustments in the medical 
prescription(2), justified by a supposed inefficacy of 
the drug which, in fact, was not used appropriately, 
which can compromise the patient’s safety in the 
medication treatment.
Patient safety(3) and adherence(4-6) to the 
pharmacological treatment are important challenges in 
care practice and require efficient nursing interventions. 
To plan and implement these actions, the patients’ 
subjectivity, needs, motivations and difficulties need to 
be considered, more than how precisely they follow the 
health team’s recommendations(7).
In the domestic context, the family serves as a 
privileged space for care practice and social support, 
which influence the treatment adherence(8). Patients and 
family members play a decisive role in the monitoring of 
the pharmacological treatment.
The construction of a theoretical model about the 
meaning of the medication treatment for schizophrenia 
patients permits a comprehensive, contextualized, 
motivational and empathetic understanding of 
the reality these individuals experience. It can 
facilitate the integration between their context, 
the meaning attributed to the drug therapy, the 
motivations, decision making and behaviors 
related to coping with the disorder, besides the 
identification of potentials and problems to follow the 
medication therapy.
Thus, this study aimed to understand the meaning 
of the medication treatment for schizophrenic patients 
and to build a theoretical model about the study 
phenomenon.
Symbolic Interactionism was employed as the 
theoretical framework. This framework presupposes 
that behavior (observable external act and internal 
experience) is guided by the individual’s definitions of 
reality. These definitions, in turn, derive from the social 
interactions in which active individuals exert mutual 
influence(9).
Method
A qualitative study was undertaken. Grounded 
Theory (GT) was used as the methodological framework. 
The systematic procedures of GT were designated 
to produce concepts and provide a multivariate 
and consistent theoretical explanation of the social 
phenomenon studied(10).
Thirty-six patients and 36 family members were 
selected to participate in the study, in a theoretical 
sampling process in which the sample structure is 
gradually defined during the data collection and 
simultaneous analysis, as recommended by the GT(10). 
Three sample groups were constituted, which came 
from community mental health services that attended 
to patients with distinct treatment experiences. These 
services were public and located in the interior of the 
State of São Paulo – Brazil.
The first sample group consisted of 15 patients 
and 15 family members from a tertiary psychiatric 
outpatient clinic that preferably attended to clinically 
more complex cases. The second sample group 
included 13 patients and 13 family members followed 
at a mental health service (secondary level), so 
as to include people with less problems due to the 
schizophrenia. In the construction process of the 
theoretical model, the need emerged for a third sample 
group, followed at a Psychosocial Care Center, as this 
service is based on another care model that, besides 
the medication treatment, includes other therapeutic 
modalities, psychosocial rehabilitation and users’ 
active participation. The inclusion of participants from 
distinct services was important to consolidate a more 
comprehensive theoretical model.
In the construction of the sample, internal 
variation in the sample groups was sought in terms 
of personal characteristics and experiences that could 
influence the construction of the meaning attributed 
to the medication use, such as: time of diagnosis, 
gender, age range, education, position in family group, 
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socioeconomic layer, religious belief, medication use, 
drug administration route, family supervision, among 
others. This variation in the composition of the groups 
facilitated the construction of the properties and 
dimensions in the categories(10).
The criteria to include patients in the study were: 
being diagnosed with schizophrenia (established by 
psychiatrist) and taking psychotropic medication(s). 
The diagnosis was confirmed with the health team and 
by consulting the patient’s history.
The criterion to include the family members in 
the study was: being mentioned by a schizophrenic 
patient who participated in the study as the family 
members most involved in the treatment. Inaptitude 
to verbally express oneself in Portuguese was used as 
an exclusion criterion for patients and relatives. The 
inclusion of family members in this study is justified 
by their potential to contribute to the understanding of 
the research phenomenon, as these participants made 
it possible to confirm and complement information 
obtained from the patients and the collection of 
additional information.
Between 2008 and 2010, data collection 
and analysis were undertaken simultaneously, as 
recommended by the GT. Recorded open interviews 
and observation were the main strategies to obtain 
the data, but were complemented by consultations of 
patient histories, home visits and case discussion with 
the health team. The participants could choose to be 
interviewed at home or in a private environment at the 
health service.
The first interview held was based on the guiding 
question: “Tell me what it is like for you to use the 
medication prescribed by the doctor from the psychiatric 
service” and, for the relative: “Tell me what it is like 
for your relative to use the medication prescribed by 
the doctor from the psychiatric service”. The guiding 
question only directed the aspect that was to be 
explored. New questions were added to clarify and 
support the experience.
The research started after receiving approval 
from the Research Ethics Committee (Process 
HCRP 10183/2007) and all recommendations 
for research involving human beings were 
complied with.
The data analysis process was developed through 
open, axial and selective coding, in accordance with 
the premises of the Grounded Theory(10). In the 
open coding, the data were fragmented into units of 
meaning, which were mutually compared, considering 
similarities and differences. This process produced 
temporary categories and subcategories. In the axial 
coding, the categories were mutually articulated and 
each interpretation was taken to the research field for 
revision or validation. The selective coding resulted 
in the construction of a theoretical model based 
on the data.
At the end of the analysis process, all of the 
study categories were combined around a central 
category, constituting a paradigm that included: causal 
conditions (events that influence the occurrence of 
the phenomenon), phenomenon (central element 
investigated), context (conditions in which the action/
interaction strategies are adopted), intervening 
conditions (conditions that facilitate or block the 
strategies adopted), action/interaction strategies 
(strategies adopted in response to the phenomenon) 
and consequences (results or expectations related to 
the action/interaction)(10).
Results and discussion
The interpretation of the present study data 
was based on the theoretical framework of Symbolic 
Interactionism(9). The interpretation of the research 
phenomenon based on this reference framework departs 
from the premise that the pharmacological treatment 
involves individuals in a symbolic interaction. In their 
interactions, schizophrenia patients attribute meaning 
to the experience of suffering from the disorder and 
following the medication treatment. All elements that 
interfere in the adherence to the drug therapy are 
defined and redefined in a dynamic and interactional 
process. The patients’ definitions in each situation 
determine the decision making about the medication 
treatment.
The analysis of the data collected in this 
study permitted the construction of a theoretical 
model centered on the phenomenon “LIVING 
WITH A HELP THAT BOTHERS”, which represents 
the meaning of the medication treatment for 
schizophrenia patients.
Figure 1 displays a diagram that illustrates the 
theoretical model about the meaning of the medication 
treatment for the schizophrenia patients, which will be 
explained next.
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Figure 1 - Diagram of the phenomenon: “Living with a help that bothers”
LIVING WITH A HELP THAT BOTHERS
Context: Going through tough days
Getting different
A hard trajectory until the diagnosis and treatment
Assuming a new identity
Living a mystery in daily life
Casual conditions: Weighing the
cost-benefit of the medication
Finding that the drug helps
Feeling impaired by the drug
Intervening conditions: Identifying
obstacles and incentives for the treatment
Accepting or denying the existence of the disorder
Identifying barriers in the access to the drug
Facing difficulties to self-administer the prescribed drugs
Interacting with relatives and friends
Interacting with the health team
Consequences: Staying in a labyrinth
Leading ones life as close to normal as possible
Experiencing the worsening of the symptoms
Remaining stagnated with the drug
Reassessing one s decisions
Action strategies:
Looking for a way out
Adhering to the drugs
Minimizing the damage the drug causes
The Context: Going through tough days
The schizophrenia patients construct the 
meaning of the medication treatment in a context 
in which they go through difficult days, marked by 
symptoms, suffering, limitations, doubts, efforts 
and concerns. This experience strongly influences 
their lives.
I was alone. I don’t have a friend, I don’t have anything 
[…] the girls (who studied at the same school) all got married, 
dated and I got like this, no family, nobody […] I keep watching 
the others date, sometimes I feel angry. […] I cannot work for 
the others anymore, I can’t. My head hurts just from watching 
the others work, drink beer. (P3)
Schizophrenia negatively influences individuals’ 
quality of life. Besides the subjective experience of the 
symptoms, it can cause significant functional losses in 
different spheres of the patients’ lives(11).
The symptoms of the disorder drive patients and 
relatives on a difficult trajectory in the attempt to 
understand what is happening and seek solutions for the 
problems they experience.
It took me five years running after things. And one thinking 
it was one thing, the other thinking it was something else. And 
things got uglier and uglier. He used to go to the neurologist, 
the psychiatrist, each gave one type of medication. But nobody 
knew what it was. […] They gave a lot of medication, but it did 
not work. And that went on until they discovered that he had 
this. (F3)
The experiences with the schizophrenia make the 
patients perceive they are different in the way they are 
known internally (by themselves) and externally (by 
other people). Thus, in a painful process, the individual 
partially takes distance from a previously constructed 
identity and build a new identity that is depreciated and 
associated with stigma and limitations.
The day he had the crisis, it’s as if he had died! He was 
alive in front of me, but it wasn’t him. It wasn’t him! He was 
another person. (F2)
Commonly, the patients experience the 
schizophrenia more than they understand it. 
They experience the impact of the schizophrenia 
concretely, in their daily life, but the disease remains a 
mystery to some.
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I have a problem in my head. I don’t know if it’s the 
neurons that are rotten, or something else. But there’s gas 
coming out of ears on both sides, like a truck with exploding 
tires, right? The head creates that pressure inside the brain […] 
Luckily there’s a discharge on both sides of the ears. If it weren’t 
for that discharge I would get barking mad. I already told the 
doctor, he laughed. […] Or it’s cancer in the head, there’s some 
disgrace. (P19)
The medication is presented to these people 
as a resource to eliminate or mitigate the suffering 
experienced because of the disorder. This context in 
which the treatment occurs provides relevant elements 
for the professionals’ activities. The literature suggests 
that peculiarities in the individuals’ context and culture 
can significantly influence the adherence. Interventions 
to optimize the adherence tend to be more effective 
when adapted to the individual needs and perceptions 
about the treatment and articulated with the factors 
permitting or impeding the adherence(12-13).
Causal conditions: Weighing the cost-benefit of the 
medication
The medication provides for the reduction of the 
symptoms, a better subjective wellbeing, quality of 
life and relationships, better socialization, activity 
performance and greater feeling of safety and self-
control. Because of these benefits and the symptoms it 
avoids, the medication gains singular importance in the 
life of schizophrenic patients.
Without the medication, perhaps I wouldn’t even be alive, 
you know. I don’t know. We don’t know our limits. I don’t know 
what I would be capable of doing. (P10)
The medication is a form of help, however, 
the patient does not want to need. It represents an 
imperfect solution, as it does not definitively extinguish 
the suffering the schizophrenia causes. In addition, the 
drug entails collateral effects, causes concerns related 
to the possibility of future damage and represents the 
obligation to constantly reaffirm the disorder.
The patients aim to definitively get rid of the 
schizophrenia, without living with the damage the 
treatment causes. Over time, however, these individuals 
conclude that they are in a situation in which their 
desires seem to be incompatible with the reality.
Ah, we think it’s bad, but what can we do? You have to 
take it. (P21)
The medication therapy symbolizes the coexistence 
between the help and the loss. The meaning attributed 
to the drug reveals the conflict the patients constantly 
experience throughout the treatment. They simply want 
to get relief, but are unable to.
This drug has caused me a lot of evil, but I need it. (P7)
It helps in daily life. But there’s the side effect too, which 
bothers in daily life as well. (P16)
Thus, in following the medication treatment, the 
schizophrenia patients perceive that they are “LIVING 
WITH A HELP THAT BOTHERS”. In the course of the 
treatment, their attitude towards the medication use 
remains biased. The family members underline the bias 
the patients express towards the medication treatment.
But there’s this: it (medication) has the collateral effect 
that will impair some things, but if you don’t take it too, what’s 
it gonna be? If it’s good for one thing, I know it will generally 
cause another damage. But what can you do... (F5)
Medication is already called drug, it fixes one thing and 
ruins another. There’s no doubt. (F6)
Ambivalently, the patient acknowledges that the 
drug is unpleasant but necessary, and constantly weighs 
the cost-benefit of the treatment in order to decide on 
whether to adhere to the medication or not.
Partial adherence and non-adherence are persistent 
problems among people taking antipsychotic drugs. 
The lack of adherence is a complex and multifactorial 
phenomenon. Although non-adherence to the treatment 
involves factors external to the patient, individual 
subjectivity is fundamental to maintain treatment in the 
long term(13-15), in line with the present study.
Intervening Conditions: Identifying obstacles and 
incentives for the treatment
When choosing to adhere to or abandon the 
pharmacological treatment, the patients identify 
obstacles and incentives for their decision to turn into 
an effective action.
Among the interviewed patients, some acknowledge 
suffering from schizophrenia, while others strongly deny 
this reality. Assimilating the existence of the disorder 
is important for the drug to be considered a useful and 
relevant resource for the schizophrenia treatment.
I do not have that schizophrenia […] and the medication 
has not changed anything. (P4)
I told the doctor that I don’t like to take medication, 
because, well, I don’t like being ill. (P8)
In the literature, the insight is frequently 
associated with treatment adherence, although there is 
no conviction as to whether this association continues in 
675
www.eerp.usp.br/rlae
Vedana KGG, Miasso AI.
the long term. In addition, the insight is a necessary but 
insufficient condition for adherence(16).
Another factor that can influence the adherence 
is medication access. The flaws in the public health 
system’s medication supply, associated with the users’ 
impossibility to purchase the drugs, can compromise the 
continuity of the drug therapy(17-18).
I stopped at that time, it was because I really was in no 
financial conditions. (P10)
The unintentional behavior of non-adherence to 
the drug therapy can be favored by the schizophrenia 
patients’ limitations to self-administer the drugs(17), 
forgetting(19) and complex therapeutic schemes(18).
That drip remedy is difficult because I can’t see. I don’t 
know how many drops fall. (P19)
He (patient) frequently did not take the medication. He 
did not pick it up, did not attend the return appointments. (F9)
Some of these problems are mitigated when the 
patient gets support from relatives, significant others 
or health professionals for the sake of medication 
administration in accordance with their needs(18).
My father, she and my other brother. These three give the 
medication, take the medication to him (patient) and remind 
him to take the medication. (F7)
The family of mental patients need support and 
preparation to cooperate with the treatment(20), as the 
family’s involvement in the support for the patient is 
fundamental for a successful treatment(18).
The quality of the bond between the health team 
and the patient can enhance or impair the maintenance 
of the drug therapy. A good therapeutic alliance among 
health professionals, family members and patients 
provides for better treatment results and reduces the 
possibility of non-adherence(6,14,21).
The physician was reliable, then I accepted to take the 
medication. (P33)
In the social interaction, the individual shares 
perspectives, defines the reality, makes decisions 
and modifies the course of their actions(9). Therefore, 
interactions can represent opportunities to reconstruct 
meanings, also with regard to the medication treatment 
and related behaviors.
Some of the factors that influence the 
pharmacological adherence can be changed(2). Therefore, 
they should be considered in the planning of strategic 
actions to promote the elements that contribute to the 
medication adherence behavior and to minimize factors 
that compromise the success of the treatment.
Action/interaction strategies: Looking for a way out
The schizophrenia patients weight the cost-benefit 
of the drug in order to select the action strategy they 
will adopt: adhering to the medication or minimizing the 
damage the drug treatment causes.
These action strategies represent the search for a 
way out, for a solution to the conflict of “LIVING WITH A 
HELP THAT BOTHERS”.
I am going through this, I don’t see any way out […]. I 
need to try something […] then I take it (the drug). (P5)
If necessary I take it, no problem. What can I do? Give up? 
If I need it... (P14)
The assessment about the continuous use of the 
drug is not static. The patients frequently analyze 
the suffering the schizophrenia causes, as well as the 
advantages and disadvantages of the drug, in which 
sometimes the “help” and sometimes the “loss” prevails. 
This assessment of the reality and the consequent option 
to adherence to the medication use or not are part of a 
dynamic and changeable process. According to Symbolic 
Interactionism, the meanings are changed in a dynamic 
process of interpretation the patients accomplish when 
coping with the situations they experience(9).
We would like not to want to take it anymore […] I have 
taken it (the medication), but I have wanted to quit. (P6)
In this context, the monitoring and motivation 
towards adherence should be highlighted(4,6), as the 
treatment adherence results from a cooperative effort 
between the health professional and the patient(7).
In some situations of “weighing the cost-benefit of 
the drug”, the patient chooses not to adhere with a view 
to reducing the damage the pharmacological treatment 
causes. This is a relevant problem that compromises 
the treatment success, as the literature appoints that 
approximately half of the schizophrenia patients do not 
adhere to the prescribed drugs(2,17).
Consequences: Staying in a labyrinth
The action strategies the patient adopts can result 
in the improvement, stabilization or worsening of the 
clinical conditions of the disorder. The results of these 
strategies, even when positive, do not fully attend to the 
patients’ expectations. “Staying in a labyrinth” is the way 
the patients feel when assessing these consequences, as 
they keep on searching for new exits and solutions. 
Since I have started the treatment, I should have been 
discharged by now. If some medicine had worked, I would already 
have improved, I would already have been cured. It seems as if 
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you’re in a labyrinth you’re trying to get out of, but then you 
explode with it. But I’m taking it (the medication). (P12)
The feeling of being in a labyrinth is experienced in 
different ways, with varying degrees of satisfaction with 
the treatment, symptoms, limits and potentials of the 
schizophrenia patients.
In seeking relief from the adherence to the drug 
therapy, the patients can reach good levels of functioning 
and lead a life “as closely to normal as possible”. In that 
context, the individuals do not feel “completely normal” 
and the drug therapy symbolizes the route to achieve 
stability and, at the same time, the existence of a 
limitation.
I am completely normal, the only problem is that I take 
medication. (P22)
I try to lead my life as closely to normal as possible. So 
I look for any means I find out there, which can help me. (P1)
Hence, it is impossible to directly relate the benefits 
of the medication with satisfaction or adherence. Studies 
indicate that positive results of drug treatment can favor 
adherence(13) but, when associated with an expected 
cure, they can arouse questions about the need to 
maintain the treatment(22). Therefore, it is not purely 
the result of the medication treatment that influences 
the adherence, but the individuals’ assessment of this 
experience.
In some situations, the schizophrenia patients feel 
as if they were stagnated while taking the medication, 
experiencing the maintenance of the clinical conditions 
of the disorder, without progresses and relapses.
It’s just that it always continues like that. […] It doesn’t 
get better but, if you don’t take it (the medication), it gets twice 
as bad. (F3)
He didn’t have any relapse, but I don’t see any progress 
either. But merely the fact that he didn’t have any relapse is 
good I think! (F9)
The option to abandon the pharmacological 
treatment can make the individuals more vulnerable to 
the exacerbation of previously controlled symptoms.
If I didn’t take it I got worse. When taking the medicine 
correctly I don’t have this kind of thing… I hear voices, I see 
visions because I stop taking the medication. (P6)
Yes, I’ve already wanted to (quit the medication) 
sometimes. We insist blindly, you see? I had to get back to the 
same place, start over. (P7)
The association between the non-adherence 
and the negative consequences is not an all-or-
nothing phenomenon, as many patients adhere 
partially. Nevertheless, the literature has shown 
a significant impact even in mild degrees of non-
adherence(6,23). Evidence exists that non-adherence 
to antipsychotic medication use is related to relapses, 
more frequent hospitalizations, worse prognoses and 
higher costs(5,23-24).
The consequences of the choices the patients 
have made in advance represent experiences they 
accumulate and consider when assessing the present 
situation and making new decisions, as human beings 
act in the present predominantly influenced by what is 
currently happening, but past experiences are applied 
in the action, according to the memories the individuals 
evoke(25). Thus, like in a labyrinth, the schizophrenia 
patients keep on searching for a way out of the dilemma 
of “LIVING WITH A HELP THAT BOTHERS”.
The experiences the patients accumulate and 
their future perspective provoked reflections about 
their behavior towards the medication treatment. 
Studies undertaken in distinct contexts certify that the 
improvement of symptoms, the prevention of relapses, 
the possibility of leading a normal life and the hope for 
the future favor the treatment adherence(13,15).
Conclusion
The act of taking a medication daily may seem 
routine and simple, but the experience is complex. 
For the schizophrenia patients, the effects of a drug 
are not limited to what the pharmacodynamics or 
pharmacokinetics can explain. As a result of the 
construction of meanings, medication use gains a larger 
dimension in the individuals’ life.
The medication treatment affects the patients not 
only in terms of biochemical aspects, but also entails 
implications for their feelings and interactions, requires 
definitions, choices, attitudes, re-evaluations and 
redefinition of subsequent actions.
The schizophrenia patients perceive that, when 
following the medication treatment, they are “LIVING 
WITH A HELP THAT BOTHERS”. Therefore, motivational 
interventions are recommended that address the 
patients’ biased attitude towards the treatment, so as to 
favor the adherence.
The interaction with the client is an appropriate 
time to reconstruct meanings and, therefore, should be 
better explored as an instrument to promote treatment 
adherence and adaptive coping with the disorder.
The adherence behavior is complex and involves a 
wide range of external and subjective factors. To reach 
677
www.eerp.usp.br/rlae
Vedana KGG, Miasso AI.
the decisive elements of treatment adherence, care 
strategies are recommended that are based on each 
client’s reality and subjectivity.
One study limitation is the confirmation of the 
diagnosis by means of secondary sources (patient history 
and health team) and the restriction to schizophrenia 
patients under treatment at public health services within 
a delimited geographic territory. The theoretical model 
formulated in this study is valid for the study sample, 
within the context chosen. Nevertheless, it signals 
elements of the medication treatment compliance 
experience, which schizophrenia patients may share in 
different contexts.
It is highlighted that the theoretical model built 
in this study is not a set of closed, terminated and 
definitive premises. The emerging theory is continuously 
developing, with the possibility of deepening and 
expansion in other studies.
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